Overview
- In early June several plaintiff firms publicly announced a securities class action over Phreesia and invited investors to join or move for lead-plaintiff status.
- The complaint covers purchases from May 8, 2025 through March 30, 2026 and says company statements concealed slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment.
- Plaintiffs assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5 for making allegedly false or misleading statements about fiscal 2027 growth projections.
- No class has been certified and investors are not represented unless they retain counsel; the deadline to move for appointment as lead plaintiff is July 13, 2026 and competing filings are expected.
- Firms are offering contingency-fee representation and say investors suffered losses when the truth reached the market, but any recovery will depend on later rulings on lead plaintiff, class certification, and proof of falsity and loss causation.